CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 119 filers reported holding CRINETICS PHARMACEUTICALS IN in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $167,252 | +25.2% | 3,573 | -4.8% | 0.01% | +16.7% |
| Q4 2023 | $133,603 | +19.6% | 3,755 | 0.0% | 0.01% | 0.0% |
| Q3 2023 | $111,674 | +117.5% | 3,755 | +31.8% | 0.01% | +200.0% |
| Q2 2023 | $51,339 | +12.2% | 2,849 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $45,755 | -21.6% | 2,849 | -10.7% | 0.00% | -33.3% |
| Q4 2022 | $58,395 | -6.8% | 3,191 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $62,671 | +5.3% | 3,191 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $59,512 | -1.8% | 3,191 | +15.5% | 0.00% | +50.0% |
| Q1 2022 | $60,626 | -82.0% | 2,762 | -76.6% | 0.00% | -60.0% |
| Q4 2021 | $335,948 | +65.2% | 11,825 | +22.4% | 0.01% | +66.7% |
| Q3 2021 | $203,343 | +11.7% | 9,660 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $182,091 | +55.0% | 9,660 | +25.7% | 0.00% | +50.0% |
| Q1 2021 | $117,442 | -5.3% | 7,686 | -12.6% | 0.00% | 0.0% |
| Q4 2020 | $124,055 | -10.0% | 8,792 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $137,771 | -10.6% | 8,792 | 0.0% | 0.00% | -33.3% |
| Q2 2020 | $154,036 | +151.1% | 8,792 | +110.7% | 0.00% | +200.0% |
| Q1 2020 | $61,343 | -41.4% | 4,173 | 0.0% | 0.00% | -50.0% |
| Q4 2019 | $104,701 | +352.8% | 4,173 | +351.1% | 0.00% | – |
| Q2 2019 | $23,125 | – | 925 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 479,681 | $21,484,912 | 8.12% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $6,315,390 | 7.68% |
| STEMPOINT CAPITAL LP | 551,095 | $24,683,545 | 7.25% |
| EcoR1 Capital, LLC | 4,155,375 | $186,119,246 | 5.69% |
| ACUTA CAPITAL PARTNERS, LLC | 135,141 | $6,052,965 | 5.10% |
| First Light Asset Management, LLC | 1,200,508 | $53,770,753 | 4.71% |
| Ikarian Capital, LLC | 588,818 | $26,373,158 | 4.59% |
| Paradigm Biocapital Advisors LP | 2,513,302 | $112,570,797 | 4.31% |
| MPM BioImpact LLC | 557,184 | $24,956,271 | 3.88% |
| Cormorant Asset Management, LP | 1,350,000 | $60,466,500 | 3.49% |